Uma “espada-de-dois-gumes”: bactérias & Covid-19 / A double-edged sword: bacterias & Covid-19

Joel Antonio Cordeiro de Abreu, Fabiana Brandão Alves Silva

Abstract


A COVID-19 é uma doença infecciosa do trato respiratório causada pelo vírus SARS-CoV-2 que infectou até o momento mais de 157 milhões de pessoas, levando à morte mais de 3,25 milhões. Diferentes medicamentos e terapias vêm sendo avaliados no tratamento e prevenção desta doença, sendo que o uso off-label de alguns medicamentos vem ocorrendo, inclusive de forma indiscriminada, como nos casos dos antibióticos, que estão sendo empregados de forma empírica na prevenção e tratamento de infecções secundárias. Estudos demonstram uma alta incidência de prescrição de antibióticos para pacientes com COVID-19, mesmo sem avaliação epidemiológica e microbiológica prévia e essa tomada de decisão pode levar à uma epidemia de micro-organismos resistentes à antimicrobianos em um cenário de pós-pandemia. Para o momento atual, ressalta-se que o uso indiscriminado de antibióticos pode levar à um desfecho clínico desfavorável, fato este que já vem sendo observado na COVID-19.


Keywords


COVID-19, Coinfecção, Antibioticoterapia Empírica.

References


- ZHU, N.; ZHANG, D.; WANG, W.; et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine, v. 382, n. 8, p. 727–733, 2020.

- WANG, MEI YUE; ZHAO, R.; GAO, L. J.; et al. SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Frontiers in Cellular and Infection Microbiology, v. 10, p. 1–17, 2020.

- DROSTEN, C.; GÜNTHER, S.; PREISER, W.; et al. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. New England Journal of Medicine, v. 348, n. 20, p. 1967–1976, 2003.

- KSIAZEK;, T. G.; ERDMAN, D.; GOLDSMITH, C. S.; et al. A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. The New England Journal of Medicine, v. 348, n. 20, p. 1953–1966, 2003.

- ZHONG, N. S.; ZHENG, B. J.; LI, Y. M.; et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet, v. 362, p. 1353–1358, 2003.

- TRINDADE, A. G.; CAXITO, S. M. C.; XAVIER, A. R. E. O.; XAVIER, M. A. S.; BRANDÃO, F. COVID-19: Therapeutic approaches description and discussion. Anais da Academia Brasileira de Ciencias, v. 92, n. 2, p. 1–15, 2020

- ZAKI, A. M.; VAN BOHEEMEN, S.; BESTEBROER, T. M.; OSTERHAUS, A. D. M. E.; FOUCHIER, R. A. M. Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia. New England Journal of Medicine, v. 367, n. 19, p. 1814–1820, 2012.

– ORGANIZAÇÃO MUNDIAL DA SAÚDE. WHO Director-General’s statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV). Disponível em: . Acesso em: 23/03/2021.

- ORGANIZAÇÃO MUNDIAL DA SAÚDE. WHO Coronavirus (COVID-19) Dashoboard. Disponível em: . Acesso em: 10/03/2021.

- BEIGEL, J. H.; TOMASHEK, K. M.; DODD, L. E.; et al. Remdesivir for the Treatment of Covid-19 — Final Report. New England Journal of Medicine, v. 383, n. 19, p. 1813–1826, 2020.

- BORBA, M. G. S.; VAL, F. F. A.; SAMPAIO, V. S.; et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Network Open, v. 3, n. 4, p. e208857, 2020.

- CAO, B.; WANG, Y.; WEN, D.; et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine, v. 382, n. 19, p. 1787–1799, 2020.

- CHACCOUR, C.; CASELLAS, A.; BLANCO-DI MATTEO, A.; et al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine, v. 32, 2021

- GAUTRET, P.; LAGIER, J.; PAROLA, P.; HOANG, V. T.; et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents, v. 56, n. 1, 2020.

- LÓPEZ-MEDINA, E.; LÓPEZ, P.; HURTADO, I. C.; et al. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial. JAMA, v. 325, n. 14, p. 1426–1435, 2021.

- SPINNER, C. D.; GOTTLIEB, R. L.; CRINER, G. J.; et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial. JAMA, v. 324, n. 11, p. 1048–1057, 2020.

- TOMAZINI, B. M.; MAIA, I. S.; CAVALCANTI, A. B.; et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial. JAMA, v. 324, n. 13, p. 1307–1316, 2020.

- VILLAR, J.; AÑÓN, J. M.; FERRANDO, C.; et al. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: Study protocol for a randomized controlled superiority trial. Trials, v. 21, n. 717, 2020.

- WANG, YEMING; ZHANG, D.; DU, G.; et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicenter trial. The Lancet, v. 395, p. 1569–1578, 2020.

- ABELENDA-ALONSO, G.; PADULLÉS, A.; ROMBAUTS, A.; et al. Antibiotic prescription during the COVID-19 pandemic: A biphasic pattern. Infection Control and Hospital Epidemiology, v. 41, n. 11, p. 1371–1372, 2020.

- CLANCY, C. J.; NGUYEN, M. H. COVID-19, superinfections and antimicrobial development: What can we expect? Clinical Infectious Diseases, v. 71, n. 17, p. 2736-2743, 2020.

- MALCOLM, W.; SEATON, R. A.; HADDOCK, G.; et al. Impact of the COVID-19 pandemic on community antibiotic prescribing in Scotland. JAC-Antimicrobial Resistance, v. 2, n. 4, 2020.

- HSU, J. How covid-19 is accelerating the threat of antimicrobial resistance. BMJ, v. 369, 2020.

- RAWSON, T. M.; MING, D.; AHMAD, R.; MOORE, L. S. P.; HOLMES, A. H. Antimicrobial use, drug-resistant infections and COVID-19. Nature Reviews Microbiology, v. 18, n. 8, p. 409–410, 2020.

- RAWSON, T. M.; MOORE, L. S. P.; ZHU, N.; et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. Clinical Infectious Diseases, v. 71, n. 9, p. 2459–2468, 2020.

- ZHANG, H.; PENNINGER, J. M.; LI, Y.; ZHONG, N.; SLUTSKY, A. S. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Medicine, v. 46, n. 4, p. 586–590, 2020.

- LU, R.; ZHAO, X.; LI, J.; et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet, v. 395, n. 10224, p. 565–574, 2020.

- HOFFMANN, M.; KLEINE-WEBER, H.; SCHROEDER, S.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Article SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, v. 181, n. 2, p. 271–280, 2020.

- SUNGNAK, W.; HUANG, N.; BÉCAVIN, C.; et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nature Medicne, v. 26, p. 681–687, 2020.

- ZOU, X.; CHEN, K.; ZOU, J.; HAN, P.; HAO, J. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Frontiers in Medicine, v. 14, n. 2, p. 185–192, 2020.

- PARASHER, A. COVID-19 : Current understanding of its pathophysiology, clinical presentation and treatment. BMJ, p. 312–320, 2020.

- WIERSINGA, W. J.; RHODES, A.; CHENG, A. C.; PEACOCK, S. J.; PRESCOTT, H. C. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA, v. 324, n. 8, p. 782–793, 2020.

- SADEGHI, A.; ASGARI, A. A.; NOROUZI, A.; et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): A randomized controlled trial. The Journal of Antimicrobial Chemotherapy, v. 75, n. 11, p. 3379–3385, 2020.

- UDWADIA, Z. F.; SINGH, P.; BARKATE, H.; PATIL, S. Efficacy and safety of favipiravir , an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19 : A randomized, comparative, open-label, multicenter, phase 3 clinical trial. International Journa of Infectious Diseases, v. 103, p. 62–71, 2020.

- WANG, YEMING; ZHOU, F.; ZHANG, D.; et al. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19 : study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. v. 21, n. 1422, 2020.

- ANDREANI, J.; LE, M.; DU, I.; JARDOT, P.; et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS- CoV-2 shows synergistic effect. Microbial Pathogenesis, v. 145, 2020.

- CALY, L.; DRUCE, J. D.; CATTON, M. G.; JANS, D. A.; WAGSTAFF, K. M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research, v. 178, 2020.

- KEYAERTS, E.; LI, S.; VIJGEN, L.; et al. Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice. Antimicrobial Agents and Chemotherapy, v. 53, n. 8, p. 3416–3421, 2009.

- VINCENT, M. J.; BERGERON, E.; BENJANNET, S.; et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virology Journal, v. 2, n. 69, 2005.

- YAO, X.; YE, F.; ZHANG, M.; et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, v. 71, n. 15, p. 732–739, 2020.

- ABD-ELSALAM, S.; ESMAIL, E. S.; KHALAF, M.; et al. Hydroxychloroquine in the treatment of COVID-19: A multicenter randomized controlled study. The American Journal of Tropical Medicine and Hygiene, v. 103, n. 4, p. 1635–1639, 2020.

- AHMED, S.; KARIM, M. M.; ROSS, A. G.; et al. A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International Journal of Infectious Diseases, v. 103, p. 214–216, 2021.

- CAVALCANTI, A. B.; ZAMPIERI, F. G.; ROSA, R. G.; et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. New England Journal of Medicine, v. 383, n. 21, p. 2041–2052, 2020

- LIU, X.; CHEN, H.; SHANG, Y.; et al. Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. Trials, v. 21, n. 622, 2020.

- SELF, W. H.; SEMLER, M. W.; LEITHER, L. M.; et al. Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients with COVID-19: A Randomized Clinical Trial. JAMA, v. 324, n. 21, p. 2165–2176, 2020.

- VALLEJOS, J.; ZONI, R.; BANGHER, M.; et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial. Trials, v. 21, n. 965, 2020.

- AGÊNCIA NACIONAL DE VIGILÂNCIA SANITÁRIA. Anvisa aprova registro da vacina da Fiocruz/AstraZeneca e de medicamento contra o coronavírus — Português (Brasil). Disponível em: . Acesso em 23/03/2021

- FEDERAL DRUG ADMINISTRATION. Center for Drug Evaluation and Research - Aplication Number 214787Orig1s000. Disponível em: . Acesso em: 23/03/2021.

- FADEL, R.; MORRISON, A. R.; VAHIA, A.; et al. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. Clinical Infectious Diseases, v. 71, n. 16, p. 2114-2120, 2020.

- HASAN, S. S.; CAPSTICK, T.; AHMED, R.; et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Review of Respiratory Medicine, v.14, n. 11, p. 1149–1163, 2020.

- LAMONTAGNE, F.; AGORITSAS, T.; MACDONALD, H.; et al. A living WHO guideline on drugs for covid-19. BMJ, 2020

- BLASI, F.; BONARDI, D.; ALIBERTI, S.; et al. Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy. Pulmonary Pharmacology and Therapeutics, v. 23, n. 3, p. 200–207, 2010.

- NADERI, N.; ASSAYAG, D.; MOSTAFAVI-POUR-MANSHADI, S. M. Y.; et al. Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease. Respiratory Medicine, v. 138, p. 129–136, 2018.

- O’REILLY, P. J.; JACKSON, P. L.; WELLS, J. M.; et al. Sputum PGP is reduced by azithromycin treatment in patients with COPD and correlates with exacerbations. BMJ Open, v. 3, n. 12, 2013.

- VERMEERSCH, K.; GABROVSKA, M.; AUMANN, J.; et al. Azithromycin during acute chronic obstructive pulmonary disease exacerbations requiring hospitalization (BACE) a multicenter, randomized, double-blind, placebo-controlled trial. American Journal of Respiratory and Critical Care Medicine, v. 200, n. 7, p. 857–868, 2019.

- PIACENTINI, G. L.; PERONI, D. G.; BODINI, A.; et al. Azithromycin reduces bronchial hyperresponsiveness and neutrophilic airway inflammation in asthmatic children: A preliminary report. Allergy and Asthma Proceedings, v. 28, n. 2, p. 194–198, 2007.

- GIELEN, V.; JOHNSTON, S. L.; EDWARDS, M. R. Azithromycin induces anti-viral responses in bronchial epithelial cells. European Respiratory Journal, v. 36, n. 3, p. 646–654, 2010.

- FURTADO, R. H. M.; BERWANGER, O.; FONSECA, H. A.; et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. The Lancet, v. 396, p. 959–967, 2020.

- ARABI, Y. M.; DEEB, A. M.; AL-HAMEED, F.; et al. Macrolides in critically ill patients with Middle East Respiratory Syndrome. International Journal of Infectious Diseases, v. 81, p. 184–190, 2019

- NORI, P.; COWMAN, K.; CHEN, V.; et al. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. Infection Control and Hospital Epidemiology, v. 42, n. 1, p. 84–88, 2021.

- WORLD HEALTH ORGANIZATION. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization, 2017. Disponível em: . .

- DEKKER, A. R. J.; VERHEIJ, T. J. M.; VAN DER VELDEN, A. W. Inappropriate antibiotic prescription for respiratory tract indications: Most prominent in adult patients. Family Practice, v. 32, n. 4, p. 401–407, 2015.

- FLEMING-DUTRA, K. E.; HERSH, A. L.; SHAPIRO, D. J.; et al. Prevalence of inappropriate antibiotic prescriptions among us ambulatory care visits, 2010-2011. JAMA, v. 315, n. 17, p. 1864–1873, 2016.

- MISURSKI, D. A.; LIPSON, D. A.; CHANGOLKAR, A. K. Inappropriate antibiotic prescribing in managed care subjects with influenza. American Journal of Managed Care, v. 17, n. 9, p. 601–608, 2011.

- BASSETTI, M.; RELLO, J.; BLASI, F.; et al. Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. International Journal of Antimicrobial Agents, v. 56, n. 6, 2020.

- BATTLE, S. E.; BRANDON BOOKSTAVER, P.; JUSTO, J. A.; et al. Association between inappropriate empirical antimicrobial therapy and hospital length of stay in Gram-negative bloodstream infections: Stratification by prognosis. Journal of Antimicrobial Chemotherapy, v. 72, n. 1, p. 299–304, 2017.

- LANSBURY, L.; LIM, B.; BASKARAN, V.; LIM, W. S. Co-Infections in People with COVID-19: A Systematic Review and Meta-Analysis. Journal of Infection, v. 81, n.2, p. 266–275, 2020.

- CHEN, N.; ZHOU, M.; DONG, X.; et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet, v. 395, n. 10223, p. 507–513, 2020.

- SONG, W.; JIA, X.; ZHANG, X.; LING, Y.; YI, Z. Co-infection in COVID-19, a cohort study. Journal of Infection, v. 82, n. 3, p. 440–442, 2021.

- SORIANO, C. V. M. C.; ORTIZ-FERNÁNDEZ, A.; CABALLERO, A. B.-O. A.; PABLO, R. DE. Low incidence of co-infection, but high incidence of ICU-acquired infections in critically ill patients with COVID-19. Journal of Infection, v. 82, n. 2, p. e20–e21, 2021.

- JOSEPH, C.; TOGAWA, Y.; SHINDO, N. Bacterial and viral infections associated with influenza. Influenza and Other Respiratory Viruses, v. 7, p. 105–113, 2013.

- VERROKEN, A.; SCOHY, A.; GÉRARD, L.; et al. Co-infections in COVID-19 critically ill and antibiotic management: A prospective cohort analysis. Critical Care, v. 24, n. 410, 2020.

- LIU, C.; WEN, Y.; WAN, W.; LEI, J.; JIANG, X. Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. International Immunopharmacology, v. 90, 2021.

- CHAARI, A.; MNIF, B.; BAHLOUL, M.; et al. Acinetobacter baumannii ventilator-associated pneumonia: Epidemiology, clinical characteristics, and prognosis factors. International Journal of Infectious Diseases, v. 17, n. 12, p. e1225–e1228, 2013.

- NHU, N. T. K.; LAN, N. P. H.; CAMPBELL, J. I.; et al. Emergence of carbapenem-resistant Acinetobacter baumanniia is the major cause of ventilator associated pneumonia in intensive care unit patients at an infectious disease hospital in southern Vietnam. Journal of Medical Microbiology, v. 63, p. 1386–1394, 2014.

- GARNACHO-MONTERO, J.; ORTIZ-LEYBA, C.; FERNÁNDEZ-HINOJOSA, E.; et al. Acinetobacter baumannii ventilator-associated pneumonia: Epidemiological and clinical findings. Intensive Care Medicine, v. 31, n. 5, p. 649–655, 2005

- MARTIN-LOECHES, I.; LISBOA, T.; RHODES, A.; et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Medicine, v. 37, n. 2, p. 272–283, 2011.

- YANG, J.; YANG, L.; LUO, R.; XU, J. Corticosteroid administration for viral pneumonia: COVID-19 and beyond. Clinical Microbiology and Infection, v. 26, p. 1171–1177, 2020

- YANG, Z.; LIU, JIALONG; ZHOU, Y.; et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. Journal of Infection, v. 81, p. e13–e20, 2020.

- VAN PAASSEN, J.; VOS, J. S.; HOEKSTRA, E. M.; et al. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Critical Care, v. 24, n. 1, p. 1–22, 2020.

- HEESOM, L.; REHNBERG, L.; NASIM-MOHI, M.; et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care. Journal of Global Antimicrobial Resistance, v. 22, p. 782–784, 2020.

- WILLIAMS, P.; MCWILLIAMS, C.; SOOMRO, K.; et al. The dynamics of procalcitonin in COVID-19 patients admitted to Intensive care unit - a multi-centre cohort study in the South West of England, UK. Journal of Infection, 2021.

– HENDI, S. BIN; MALIK, Z. A.; KHAMIS, A. H.; AL-NAJJAR, F. Y. A. High diagnostic accuracy of automated rapid Strep A test reduces antibiotic prescriptions for children in the United Arab Emirates. BMC Pediatrics, v. 21, n. 52, 2021.

- CHAHWAKILIAN, P.; HUTTNER, B.; SCHLEMMER, B.; HARBARTH, S. Impact of the French campaign to reduce inappropriate ambulatory antibiotic use on the prescription and consultation rates for respiratory tract infections. Journal of Antimicrobial Chemotherapy, v. 66, n. 12, p. 2872–2879, 2011.

- KLEIN, E. Y.; SCHUELLER, E.; TSENG, K. K.; et al. The impact of influenza vaccination on antibiotic use in the United States, 2010-2017. Open Forum Infectious Diseases, v. 7, n. 7, 2020.

- CHOI, P. W.; BENZER, J. A.; COON, J.; EGWUATU, N. E.; DUMKOW, L. E. Impact of pharmacist-led selective audit and feedback on outpatient antibiotic prescribing for UTIs and SSTIs. American Journal of Health-System Pharmacy, 2021.

- GOFF, D. A.; ASHIRU-OREDOPE, D.; CAIRNS, K. A.; et al. Global contributions of pharmacists during the COVID-19 pandemic. Journal of the American College of Clinical Pharmacy, 2020.




DOI: https://doi.org/10.34117/bjdv.v7i5.30577

Refbacks

  • There are currently no refbacks.